<DOC>
	<DOCNO>NCT01290679</DOCNO>
	<brief_summary>The purpose study investigate effectiveness safety TMC435 compare placebo participant infect genotype 1 hepatitis C virus never receive treatment . Participants also receive peginterferon alfa-2a peginterferon alfa-2b ribavirin part treatment .</brief_summary>
	<brief_title>An Efficacy , Safety , Tolerability Study TMC435 Treatment-naive , Genotype 1 Hepatitis C-infected Participants</brief_title>
	<detailed_description>This randomize , double-blind ( neither physician participant know name assigned drug ) , placebo-controlled study TMC435 participant infect genotype 1 hepatitis C virus never receive treatment . Participants study also receive two drug infection ( either peginterferon alfa-2a ( Pegasys® ) ribavirin ( Copegus® ) peginterferon alfa-2b ( PegIntron® ) ribavirin ( Rebetol® ) . The purpose study investigate TMC435 superior placebo reduce hepatitis C virus undetectable level 24 week end treatment . For first 12 week , participant take TMC435 placebo , plus peginterferon ribavirin . For next 12 week , participant take peginterferon ribavirin . After , participant continue take peginterferon ribavirin 24 additional week . Other participant stop take peginterferon ribavirin . The study doctor inform participant take study medication stop taking . After participant stop take study medication , continue come doctor 's office study visit total 72 week enroll study . The total duration study 78 week ( include screen ) . Participants monitor safety throughout study . Study assessment study visit may include limited : blood urine collection testing , electrocardiogram ( ECG ) assessment ( measurement electrical activity heart ) , participant questionnaire , physical examination . TMC435 take oral capsule 150 mg per day . Peginterferon ( Pegasys ® ) give injection 180 µg week . Peginterferon ( PegIntron® ) give injection week dose depend body weight . Ribavirin take tablet ( Copegus ® ) capsule ( Rebetol ® ) twice day dose depend body weight .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Genotype 1 hepatitis C infection ( confirmed screening ) Participant receive prior treatment hepatitis C Participant must liver biopsy within 3 year screen ( screen baseline visit ) show chronic hepatitis C infection Must agree use 2 form effective contraception throughout study ( male female ) Infection HIV non genotype 1 hepatitis C Liver disease relate hepatitic C infection Hepatic decompensation Significant laboratory abnormality active disease Pregnant planning become pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>TMC435</keyword>
	<keyword>HCV</keyword>
	<keyword>Hep C</keyword>
	<keyword>genotype 1</keyword>
</DOC>